Top

Published in:

01-12-2007

Peptide YY and Glucagon-like Peptide-1 in Morbidly Obese Patients Before and After Surgically Induced Weight Loss

Authors: Thomas Reinehr, Christian L. Roth, Gerit-Holger Schernthaner, Hans-Peter Kopp, Stefan Kriwanek, Guntram Schernthaner

Published in: Obesity Surgery | Issue 12/2007

Abstract

Background

Peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) are cosecreted in the same enteroendocrine L-cells of the gut and reported to inhibit food intake additively. However, findings in human studies regarding these peptides are controversial. The aim of this study was to analyze the relationships between fasting PYY, GLP-1, and weight status in morbidly obese patients before and after surgically induced weight loss.

Methods

Fasting GLP-1, PYY, glucose, and insulin concentrations; blood pressure; and body-mass index (BMI) were determined in 30 morbidly obese adults (mean BMI 45.8, mean age 40 years) before bariatric surgery [Roux-en-Y gastric bypass (RYGB): n = 19; gastric banding (GB): n = 11] and after weight loss (mean 50% excess weight loss) in the course of mean 2 years.

Results

GLP-1 concentrations decreased (mean −20 pg/ml; mean −38%; p = 0.001) and PYY concentrations increased (mean +19 pg/ml; mean +19%, p = 0.036) after bariatric surgery. The weight loss and changes of GLP-1 were significantly (p < 0.05) more pronounced after RYGB as compared to GB, whereas the changes of PYY did not differ significantly between the patients who had undergone RYGB or GB.

Conclusions

In morbidly obese adults reducing their weight by bariatric surgery, fasting PYY levels increased and GLP-1 concentrations decreased independently of each other. Therefore, the relationship between PYY and GLP-1 seems more complicated than might be anticipated from animal and in vitro studies.

Wynne K, Stanley S, Bloom S. The gut and regulation of body weight. J Clin Endocrinol Metab 2004;89:2576–82.PubMedCrossRef

Kim BJ, Carlson OD, Jang HJ, Elahi D, Berry C, Egan JM. Peptide YY is secreted after oral glucose administration in a gender-specific manner. J Clin Endocrinol Metab 2005;90:6665–71.PubMedCrossRef

Roth KA, Cohn SM, Rubin DC, Trahair JF, Neutra MR, Gordon JI. Regulation of gene expression in gastric epithelial cell populations of fetal, neonatal, and adult transgenic mice. Am J Physiol 1992;263:G186–97.PubMed

Anini Y, Fu-Cheng X, Cuber JC, Kervran A, Chariot J, Roz C. Comparison of the postprandial release of peptide YY and proglucagon-derived peptides in the rat. Pflugers Arch 1999;438:299–306.PubMedCrossRef

Neary NM, Small CJ, Druce MR, Park AJ, Ellis SM, Semjonous NM, et al. Peptide YY3-36 and glucagon-like peptide-17–36 inhibit food intake additively. Endocrinology 2005;146:5120–7.PubMedCrossRef

Nonaka N, Shioda S, Niehoff ML, Banks WA. Characterization of blood–brain barrier permeability to PYY3-36 in the mouse. J Pharmacol Exp Ther 2003;306:948–53.PubMedCrossRef

Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, et al. Gut hormone PYY (3–36) physiologically inhibits food intake. Nature 2002;418:650–4.PubMedCrossRef

Martin JR. Peptide YY administration into the posterior hypothalamic nucleus of the rat evokes cardiovascular changes by non-adrenergic, non-cholinergic mechanisms. Auton Autacoid Pharmacol 2005;25:53–67.PubMedCrossRef

Spinazzi R, Andreis PG, Nussdorfer GG. Neuropeptide-Y and Y-receptors in the autocrine–paracrine regulation of adrenal gland under physiological and pathophysiological conditions (review). Int J Mol Med 2005;15:3–13.PubMed

10.

Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003;349:941–8.PubMedCrossRef

11.

Roth CL, Enriori PJ, Harz K, Woelfle J, Cowley MA, Reinehr T. Peptide YY is a regulator of energy homeostasis in obese children before and after weight loss. J Clin Endocrinol Metab 2005;90:6386–91.PubMedCrossRef

12.

Pfluger PT, Kampe J, Castaneda TR, Vahl T, D’Alessio DA, Kruthaupt T, et al. Effect of human body weight changes on circulating levels of peptide YY and peptide YY3-36. J Clin Endocrinol Metab 2007;92:583–8.PubMedCrossRef

13.

Tschop M, Castaneda TR, Joost HG, Thone-Reineke C, Ortmann S, Klaus S, et al. Physiology: does gut hormone PYY3-36 decrease food intake in rodents? Nature 2004;430:1.PubMed

14.

Bojanowska E. Physiology and pathophysiology of glucagon-like peptide-1 (GLP-1): the role of GLP-1 in the pathogenesis of diabetes mellitus, obesity, and stress. Med Sci Monit 2005;11:RA271–8.PubMed

15.

Ballantyne GH. Peptide YY(1–36) and peptide YY(3–36): part II. Changes after gastrointestinal surgery and bariatric surgery. Obes Surg 2006;16:795–803.PubMedCrossRef

16.

Meier JJ, Gallwitz B, Schmidt WE, Nauck MA. Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives. Eur J Pharmacol 2002;440:269–79.PubMedCrossRef

17.

Gutzwiller JP, Degen L, Heuss L, Beglinger C. Glucagon-like peptide 1 (GLP-1) and eating. Physiol Behav 2004;82:17–9.PubMedCrossRef

18.

Valverde I, Villanueva-Penacarrillo ML, Malaisse WJ. Pancreatic and extrapancreatic effects of GLP-1. Diabetes Metab 2002;28:3S85–9.PubMed

19.

National Institute of Health. Gastrointestinal surgery for severe obesity: NIH consensus development conference statement. Am J Clin Nutr 1992;55:615S–9S.

20.

Naslund E, Gryback P, Hellström PM, Jacobsson H, Holst JJ, Theodorson E, et al. Gastrointestinal hormones and gastric emptying 20 years after jejeunoileal bypass for massive obesity. Int J Obes Relat Metab Disord 1997;21:387–92.PubMedCrossRef

21.

Chan JL, Stoyneva V, Kelesidis T, Raciti P, Mantzoros CS. Peptide YY levels are decreased by fasting and elevated following caloric intake but are not regulated by leptin. Diabetologia 2006;49:169–73.PubMedCrossRef

22.

Anini Y, Brubaker PL. Role of leptin in the regulation of glucagon-like peptide-1 secretion. Diabetes 2003;52:252–9.PubMedCrossRef

23.

Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998;395:763–70.PubMedCrossRef

24.

Barrenetxe J, Villaro AC, Guembe L, Pascual I, Munoz-Navas M, Barber A, et al. Distribution of the long leptin receptor isoform in brush border, basolateral membrane, and cytoplasm of enterocytes. Gut 2002;50:797–802.PubMedCrossRef

25.

Sobhani I, Bado A, Vissuzaine C, Buyse M, Kermorgant S, Laigneau JP, et al. Leptin secretion and leptin receptor in the human stomach. Gut 2000;47:178–83.PubMedCrossRef

26.

Adam TC, Jocken J, Westerterp-Plantenga MS. Decreased glucagon-like peptide 1 release after weight loss in overweight/obese subjects. Obes Res 2005;13:710–6.PubMed

27.

Reinehr T, de Sousa G, Roth CL. Fasting glucagon-like peptide-1 and its relation to insulin in obese children before and after weight loss. J Pediatr Gastroenterol Nutr 2007;44:608–12.PubMedCrossRef

28.

Rubino F, Gagner M, Gentileschi P, Kini S, Fukuyama S, Feng J, et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 2004;240:236–42.PubMedCrossRef

29.

le Roux CW, Aylwin SJ, Batterham RL, Borg CM, Coyle F, Prasad V, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 2006;243:108–14.PubMedCrossRef

30.

Morinigo R, Lacy AM, Casamitjana R, Delgado S, Gomis R, Vidal J. GLP-1 and changes in glucose tolerance following gastric bypass surgery in morbidly obese subjects. Obes Surg 2006;16:1594–601.PubMedCrossRef

31.

Alvarez Bartolome M, Borque M, Martinez-Sarmiento J, Aparicio E, Hernandez C, Cabrerizo L, et al. Peptide YY secretion in morbidly obese patients before and after vertical banded gastroplasty. Obes Surg 2002;12:324–7.PubMedCrossRef

32.

Korner J, Inabnet W, Conwell IM, Taveras C, Daud A, Olivero-Rivera L, et al. Differential effects of gastric bypass and banding on circulating gut hormone and leptin levels. Obesity (Silver Spring) 2006;14:1553–61.CrossRef

33.

Brynes AE, Frost GS, Edwards CM, Ghatei MA, Bloom SR. Plasma glucagon-like peptide-1 (7–36) amide (GLP-1) response to liquid phase, solid phase, and meals of differing lipid composition. Nutrition 1998;14:433–6.PubMedCrossRef

34.

Morinigo R, Moize V, Musri M, Lacy AM, Navarro S, Marin JL, et al. Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2006;91:1735–40.PubMedCrossRef

Title: Peptide YY and Glucagon-like Peptide-1 in Morbidly Obese Patients Before and After Surgically Induced Weight Loss
Authors: Thomas Reinehr
Christian L. Roth
Gerit-Holger Schernthaner
Hans-Peter Kopp
Stefan Kriwanek
Guntram Schernthaner
Publication date: 01-12-2007
Publisher: Springer-Verlag
Published in: Obesity Surgery / Issue 12/2007
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI: https://doi.org/10.1007/s11695-007-9323-8

At a glance: The STEP trials

Springer Medicine

Peptide YY and Glucagon-like Peptide-1 in Morbidly Obese Patients Before and After Surgically Induced Weight Loss

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2007

Prophylaxis of Thromboembolism in Bariatric Surgery with Parnaparin

Increase in Ghrelin Levels After Weight Loss in Obese Zucker Rats is Prevented by Gastric Banding

Clinical Pathway for Laparoscopic Gastric Bypass

Who Benefits from Gastric Banding?

Metabolic and Nutritional Status Changes After 10% WeightLoss in Severely Obese Patients Treated with Laparoscopic Surgery vs Integrated Medical Treatment

Gender Differences in Early Outcomes Following Hand-Assisted Laparoscopic Roux-en-Y Gastric Bypass Surgery